Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Krysiak R, Basiak M, Szkróbka W, Okopień B. The impact of rosuvastatin on hypothalamic-pituitary-testicular axis activity in metformin-treated and metformin-naïve men with low testosterone levels: a pilot study. Pharmacol Rep 2021;73:1465-1472. [PMID: 34086261 PMCID: PMC8460565 DOI: 10.1007/s43440-021-00289-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Revised: 05/25/2021] [Accepted: 05/27/2021] [Indexed: 11/27/2022]

For:	Krysiak R, Basiak M, Szkróbka W, Okopień B. The impact of rosuvastatin on hypothalamic-pituitary-testicular axis activity in metformin-treated and metformin-naïve men with low testosterone levels: a pilot study. Pharmacol Rep 2021;73:1465-1472. [PMID: 34086261 PMCID: PMC8460565 DOI: 10.1007/s43440-021-00289-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Revised: 05/25/2021] [Accepted: 05/27/2021] [Indexed: 11/27/2022]

Number

Cited by Other Article(s)

Men J, Zhang L, Peng R, Li Y, Li M, Wang H, Zhao L, Zhang J, Wang H, Xu X, Dong J, Wang J, Yao B, Guo J. Metformin Ameliorates 2.856 GHz Microwave- Radiation-Induced Reproductive Impairments in Male Rats via Inhibition of Oxidative Stress and Apoptosis. Int J Mol Sci 2023;24:12250. [PMID: 37569626 PMCID: PMC10418945 DOI: 10.3390/ijms241512250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Revised: 07/25/2023] [Accepted: 07/27/2023] [Indexed: 08/13/2023] Open

Affiliation(s)

Junqi Men PLA Center for Disease Control and Prevention, Beijing 100071, China; (J.M.); (L.Z.) Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China; (R.P.); (Y.L.); (M.L.); (H.W.); (L.Z.); (J.Z.); (H.W.); (X.X.); (J.D.); (J.W.) School of Public Health, China Medical University, Shenyang 110122, China
Li Zhang PLA Center for Disease Control and Prevention, Beijing 100071, China; (J.M.); (L.Z.)
Ruiyun Peng Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China; (R.P.); (Y.L.); (M.L.); (H.W.); (L.Z.); (J.Z.); (H.W.); (X.X.); (J.D.); (J.W.)
Yanyang Li Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China; (R.P.); (Y.L.); (M.L.); (H.W.); (L.Z.); (J.Z.); (H.W.); (X.X.); (J.D.); (J.W.)
Meng Li Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China; (R.P.); (Y.L.); (M.L.); (H.W.); (L.Z.); (J.Z.); (H.W.); (X.X.); (J.D.); (J.W.)
Hui Wang Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China; (R.P.); (Y.L.); (M.L.); (H.W.); (L.Z.); (J.Z.); (H.W.); (X.X.); (J.D.); (J.W.)
Li Zhao Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China; (R.P.); (Y.L.); (M.L.); (H.W.); (L.Z.); (J.Z.); (H.W.); (X.X.); (J.D.); (J.W.)
Jing Zhang Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China; (R.P.); (Y.L.); (M.L.); (H.W.); (L.Z.); (J.Z.); (H.W.); (X.X.); (J.D.); (J.W.)
Haoyu Wang Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China; (R.P.); (Y.L.); (M.L.); (H.W.); (L.Z.); (J.Z.); (H.W.); (X.X.); (J.D.); (J.W.)
Xinping Xu Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China; (R.P.); (Y.L.); (M.L.); (H.W.); (L.Z.); (J.Z.); (H.W.); (X.X.); (J.D.); (J.W.)
Ji Dong Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China; (R.P.); (Y.L.); (M.L.); (H.W.); (L.Z.); (J.Z.); (H.W.); (X.X.); (J.D.); (J.W.)
Juan Wang Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China; (R.P.); (Y.L.); (M.L.); (H.W.); (L.Z.); (J.Z.); (H.W.); (X.X.); (J.D.); (J.W.)
Binwei Yao Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China; (R.P.); (Y.L.); (M.L.); (H.W.); (L.Z.); (J.Z.); (H.W.); (X.X.); (J.D.); (J.W.)
Jiabin Guo PLA Center for Disease Control and Prevention, Beijing 100071, China; (J.M.); (L.Z.) School of Public Health, China Medical University, Shenyang 110122, China

Collapse

Krysiak R, Kowalcze K, Okopień B. Rosuvastatin potentiates the thyrotropin-lowering effect of metformin in men with non-autoimmune subclinical hypothyroidism and prediabetes. J Clin Pharm Ther 2022;47:2030-2040. [PMID: 35899679 DOI: 10.1111/jcpt.13746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Revised: 05/28/2022] [Accepted: 07/10/2022] [Indexed: 12/24/2022]

Abstract

WHAT IS KNOWN AND OBJECTIVE

Metformin treatment decreases thyrotropin levels in individuals with hypothyroidism and this effect seems to be mediated by the 5'-adenosine monophosphate-activated protein kinase pathway in the pituitary. The activity of this pathway is also stimulated by statins. The current study was aimed at investigating whether the impact of metformin on hypothalamic-pituitary-thyroid axis activity is affected by statin use.

METHODS

The study included three matched groups of men with non-autoimmune hypothyroidism and prediabetes: patients treated for at least 6 months with high-intensity rosuvastatin therapy (20-40 mg daily) [groups A (n = 24) and C (n = 19)] and men not receiving statin therapy [group B (n = 24)]. Over the entire study period (6 months), groups A and B received metformin (2.55-3 g daily). Moreover, groups A and C continued rosuvastatin therapy. The lipid profile, glucose homeostasis markers, and plasma concentrations of thyrotropin, total and free thyroid hormones, prolactin, FSH, LH, ACTH and insulin-like growth factor-1 were determined at baseline and 6 months later.

RESULTS AND DISCUSSION

Fifty-nine patients completed the study. There were differences between groups A and C and group B in baseline values of total cholesterol, LDL-cholesterol, gonadotropins and ACTH. Although observed in both groups of metformin-treated patients, the effect on thyrotropin levels was more pronounced in group A than in group B. The impact on fasting glucose and insulin sensitivity was stronger in group B than group A. In turn, only in group A metformin tended to reduce gonadotropin levels. There were no differences between follow-up and baseline values of lipids, total and free thyroid hormones, prolactin, ACTH and insulin-like growth factor-1 in both these groups. In group C, all assessed variables remained at a similar level.

WHAT IS NEW AND CONCLUSION

The results of the current study suggest that rosuvastatin potentiates the inhibitory effect of metformin on thyrotrope secretory function.

Collapse

Krysiak R, Kowalcze K, Okopień B. Hypothalamic-pituitary-gonadal axis and sexual functioning in metformin-treated men after discontinuation of testosterone replacement therapy: A pilot study. J Clin Pharm Ther 2021;46:1764-1775. [PMID: 34490645 DOI: 10.1111/jcpt.13528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2021] [Revised: 08/02/2021] [Accepted: 08/26/2021] [Indexed: 11/28/2022]

Abstract

WHAT IS KNOWN AND OBJECTIVE

Metformin was found to reduce elevated gonadotropin levels. The aim of the present study was to determine whether metformin modulates the impact of discontinuation of testosterone therapy on hypothalamic-pituitary-gonadal axis activity and sexual function in men with low testosterone levels.

METHODS

The study included 28 men with late-onset hypogonadism (defined according to the criteria of the European Male Aging Study group) receiving testosterone undecanoate (120 mg in three equal doses), 12 of whom had been treated with oral metformin (1.7-3 g daily). Both testosterone and metformin had been administered for at least six months before enrolment. In all patients, testosterone replacement required to be discontinued. The control group included 16 testosterone- and metformin-treated men with late-onset hypogonadism who during the entire study period continued their treatment. Glucose homeostasis markers, as well as plasma levels of insulin, gonadotropins, testosterone, calculated bioavailable testosterone, dehydroepiandrosterone-sulphate, oestradiol, thyrotropin, free thyroxine, prolactin, insulin-growth factor-1 and cortisol were measured at the beginning of the study and four months later. Moreover, at the beginning and the end of the study, all enrolled patients completed a questionnaire assessing their sexual functioning (IIEF-15).

RESULTS AND DISCUSSION

Discontinuation of testosterone therapy resulted in a decrease in total testosterone and bioavailable testosterone (by 42% and 45% in metformin-treated patients, and by 52% and 54% in metformin-naïve patients), as well as impaired all aspects of male sexual function. Changes in bioavailable testosterone, as well as in erectile function, orgasmic function and sexual desire were less pronounced if subjects received metformin. Only in metformin-naïve men, follow-up FSH and LH levels were higher than at baseline (by 75% and 62%). Moreover, discontinuation of testosterone therapy in metformin-naïve men increased glycated haemoglobin, as well as worsened insulin sensitivity. There were no differences between baseline and follow-up levels of the remaining hormones. In metformin-naïve subjects, the increase in gonadotropin levels correlated with the changes in testosterone levels and insulin sensitivity. No effect on glucose homeostasis markers, hormone levels and sexual functioning was observed in the control group.

WHAT IS NEW AND CONCLUSION

The obtained results suggest that metformin treatment mitigates the unfavourable effect of discontinuation of testosterone treatment on hypothalamic-pituitary-testicular axis activity and sexual function in men with late-onset hypogonadism.

Collapse